MX2019003366A - Ajuste de la dosis. - Google Patents

Ajuste de la dosis.

Info

Publication number
MX2019003366A
MX2019003366A MX2019003366A MX2019003366A MX2019003366A MX 2019003366 A MX2019003366 A MX 2019003366A MX 2019003366 A MX2019003366 A MX 2019003366A MX 2019003366 A MX2019003366 A MX 2019003366A MX 2019003366 A MX2019003366 A MX 2019003366A
Authority
MX
Mexico
Prior art keywords
dose adjustment
dose
adjustment
pibrentasvir
glecaprevir
Prior art date
Application number
MX2019003366A
Other languages
English (en)
Inventor
Liu Wei
Dutta Sandeep
Kosloski Matthew
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2019003366A publication Critical patent/MX2019003366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta solicitud presenta el ajuste de la dosis para fármacos administrados conjuntamente con glecaprevir y pibrentasvir.
MX2019003366A 2016-09-23 2017-09-22 Ajuste de la dosis. MX2019003366A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398724P 2016-09-23 2016-09-23
US201762510936P 2017-05-25 2017-05-25
PCT/US2017/052994 WO2018057919A1 (en) 2016-09-23 2017-09-22 Dose adjustment

Publications (1)

Publication Number Publication Date
MX2019003366A true MX2019003366A (es) 2019-07-04

Family

ID=61687385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003366A MX2019003366A (es) 2016-09-23 2017-09-22 Ajuste de la dosis.

Country Status (10)

Country Link
US (1) US20180085330A1 (es)
EP (1) EP3515442A4 (es)
JP (2) JP2019529426A (es)
CN (1) CN109715161A (es)
AU (2) AU2017332771A1 (es)
BR (1) BR112019005725A2 (es)
CA (1) CA3037719A1 (es)
MA (1) MA46292A (es)
MX (1) MX2019003366A (es)
WO (1) WO2018057919A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
RU2014120981A (ru) * 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
SG11201507364SA (en) * 2013-03-14 2015-10-29 Abbvie Inc Combination of two antivirals for treating hepatitis c
CA2942823C (en) * 2014-04-02 2023-01-03 Abbvie Inc. Methods for treating hcv
CN107531739A (zh) * 2015-03-02 2018-01-02 美迪维尔公司 作为用于治疗丙型肝炎的hcv抑制剂的核苷酸衍生物
KR101756050B1 (ko) * 2015-03-04 2017-07-07 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물

Also Published As

Publication number Publication date
AU2022202895A1 (en) 2022-05-26
JP2022153655A (ja) 2022-10-12
JP2019529426A (ja) 2019-10-17
BR112019005725A2 (pt) 2019-07-09
MA46292A (fr) 2019-07-31
CN109715161A (zh) 2019-05-03
US20180085330A1 (en) 2018-03-29
WO2018057919A1 (en) 2018-03-29
EP3515442A1 (en) 2019-07-31
EP3515442A4 (en) 2020-05-06
CA3037719A1 (en) 2018-03-29
AU2017332771A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
GEP20217239B (en) Pharmaceutical composition
CA2956871C (en) Compounds active towards bromodomains
EP3463248A4 (en) DEVICES AND METHOD FOR USING MEDICAL DEVICES
IL275102A (en) Devices and methods for administering a precise dose
EP3188213A4 (en) Electron source, x-ray source and device using x-ray source
GB2541571A (en) Pharmaceutical compositions
EP3660040A3 (en) Insulin receptor partial agonists
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
EP3566686A4 (en) DRUG SUPPLY
EP3560387A4 (en) CHAIR AND CHAIR COVER ELEMENT
GEP20217240B (en) Pharmaceutical composition
MX2020004424A (es) Formulacion aerosolizable.
EP3512553A4 (en) KLRG1 DEPLETION THERAPY
MX2017012553A (es) Compuestos espirociclicos.
EP3556381A4 (en) MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND ITS USES
PH12017500602A1 (en) Methods for treating ocular conditions
EP3302478A4 (en) PAC-1 COMBINATION THERAPY
MX2019015167A (es) Farmacos antivirales.
EP3534987A4 (en) ADJUSTABLE-DOSE DRUG DELIVERY SYSTEM
EP3541405A4 (en) NEW ANTIMICROBIAL AND ANTI-CANCER THERAPY